This phenotypic response was evident in KAT-4 carcinomas after a 10-day treatment period with 3G9 IgG (akin to the effects of the specific TGF-β1 and -β3 inhibitor Fc:TβRII [18, 37]), the same effect was observed in the Capan-2 model albeit after a longer treatment period with 3G9 IgG. The gene discussed is TGFBR2; the disease is carcinoma.